Analysis of effects and pharmacokinetics of subcutaneously administered BDNF.
Brain-derived neurotrophic factor (BDNF) belongs to the neurotrophin family and has been shown to be a potent and effective trophic factor for motor neurons and other neurons of the peripheral and central nervous. Little is known, however, about the relationship between the efficacy and pharmacokinetics of s.c. administered BDNF. In this study, the efficacy of BDNF on motor neuron protection in sciatic or facial nerve axotomy models was examined and compared with the concommitant concentrations of BDNF in plasma. Delayed treatment (started at 1 week after surgery) of BDNF was also shown to retard choline acetyltransferase reduction in sciatic nerve axotomy models.
Kishino
A
A
Sumitomo Pharmaceuticals Research Division, Osaka, Japan.
Katayama
N
N
Ishige
Y
Y
Yamamoto
Y
Y
Ogo
H
H
Tatsuno
T
T
Mine
T
T
Noguchi
H
H
Nakayama
C
C
D000818:Animals; D019771:Axotomy; D019208:Brain-Derived Neurotrophic Factor / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology*; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D020220:Facial Nerve Injuries / Q000188:drug therapy / Q000473:pathology; D007279:Injections, Subcutaneous; D008297:Male; D009046:Motor Neurons / Q000187:drug effects; D018696:Neuroprotective Agents / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D012584:Sciatic Nerve / Q000293:injuries
D019208:Brain-Derived Neurotrophic Factor; D018696:Neuroprotective Agents; D002795:Choline O-Acetyltransferase